Table 3.
Comparison between non-T2DM patients and T2DM patients with different GC status after matching
| Variables | Non-T2DM vs. Poor GC-T2DM | Non-T2DM vs. Moderate GC-T2DM | Non-T2DM vs. Well GC-T2DM | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-T2DM | Poor GC-T2DM | P | Non-T2DM | Moderate GC-T2DM | P | Non-T2DM | Well GC-T2DM | P | |
| n | 98 | 98 | 136 | 136 | 163 | 163 | |||
| Age (years) | 60.13 ± 12.26 | 65.67 ± 9.32 | 0.001 | 62 (56.00, 67.00) | 68 (57.00, 74.00) | 0.001 | 64.44 ± 10.71 | 67.57 ± 11.23 | 0.010 |
| Male sex, n (%) | 47 (48.0) | 52 (53.1) | 0.475 | 63 (46.3) | 75 (55.1) | 0.146 | 69 (42.3) | 94 (57.7) | 0.577 |
| Body mass index (kg/m2) | 23.75 (22.14, 26.32) | 24.69 (22.44, 26.71) | 0.180 | 24.28 (22.79, 26.03) | 24.68 (22.57, 26.48) | 0.856 | 24.31 (22.04, 26.30) | 24.44 (22.49, 26.57) | 0.495 |
| Smoking, n (%) | 25 (25.5) | 22 (22.4) | 0.616 | 29 (21.3) | 31 (22.8) | 0.770 | 36 (22.1) | 34 (20.9) | 0.787 |
| Hypertension, n (%) | 58 (59.2) | 64 (65.3) | 0.377 | 84 (61.8) | 87 (64.0) | 0.707 | 108 (66.3) | 96 (58.9) | 0.170 |
| Dyslipidemia, n (%) | 57 (58.2) | 52 (53.1) | 0.472 | 65 (47.8) | 58 (42.6) | 0.394 | 60 (36.8) | 61 (37.4) | 0.909 |
| Statin, n (%) | 61 (62.2) | 73 (74.5) | 0.065 | 80 (58.8) | 102 (75.0) | 0.005 | 95 (58.3) | 119 (73.0) | 0.005 |
| Tube voltage of CT acquisition | 0.883 | 0.848 | 0.663 | ||||||
| 100 kVp, n (%) | 52 (53.1) | 54 (55.1) | 67 (49.3) | 71 (52.2) | 85 (52.1) | 93 (57.1) | |||
| 120 kVp, n (%) | 43 (43.9) | 42 (42.9) | 65 (47.8) | 62 (45.6) | 73 (44.8) | 66 (40.5) | |||
| 140 kVp, n (%) | 3 (3.1) | 2 (2.0) | 4 (2.9) | 3 (2.2) | 9 (3.1) | 4 (2.5) | |||
| CAD-RADS category | 0.407 | 0.866 | 0.065 | ||||||
| CAD-RADS 0, n (%) | 21 (21.4) | 14 (14.3) | 32 (23.5) | 36 (26.5) | 49 (30.1) | 49 (30.1) | |||
| CAD-RADS 1, n (%) | 8 (8.2) | 6 (6.1) | 8 (5.9) | 10 (7.4) | 6 (3.7) | 15 (9.2) | |||
| CAD-RADS 2, n (%) | 34 (34.7) | 43 (43.9) | 59 (43.4) | 52 (38.2) | 57 (35.0) | 64 (39.3) | |||
| CAD-RADS 3, n (%) | 28 (28.6) | 28 (28.6) | 26 (19.1) | 30 (22.1) | 35 (21.5) | 28 (17.2) | |||
| CAD-RADS 4, n (%) | 7 (7.1) | 5 (5.1) | 8 (5.9) | 5 (3.7) | 15 (9.2) | 5 (3.1) | |||
| CAD-RADS 5, n (%) | 0 (0.0) | 2 (2.0) | 3 (2.2) | 3 (2.2) | 1 (0.6) | 2 (1.2) | |||
| LAD-PCAT (HU) | − 74.83 ± 7.82 | − 77.15 ± 8.07 | 0.067 | − 77.21 ± 7.01 | − 77.25 ± 7.86 | 0.996 | − 79.02 ± 7.99 | − 77.73 ± 7.75 | 0.185 |
| LCX-PCAT (HU) | − 68.75 ± 7.59 | − 71.93 ± 7.25 | 0.008 | − 71.09 ± 6.55 | − 71.14 ± 7.40 | 0.958 | − 71.73 ± 8.39 | − 71.70 ± 7.57 | 0.972 |
| RCA-PCAT (HU) | − 74.37 ± 8.44 | − 77.20 ± 7.42 | 0.026 | − 76.91 ± 7.98 | − 77.07 ± 7.96 | 0.881 | − 76.38 ± 8.91 | − 77.33 ± 7.28 | 0.340 |
Data are presented as means ± standard deviations or the median (25th and 75th percentile), with the interquartile range in parentheses or number (%)
T2DM type 2 diabetes mellitus, GC glycemic control, CAD-RADS coronary artery disease-reporting and data system, PCAT Pericoronary adipose tissue, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery